In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients

New Microbiologica

Volumn 28, Issue 4, 2005, Pages 319-326

  Gianotti, Nicola ^a,c   Galli, Laura ^a   Boeri, Enzo ^b   Maillard, Myriam ^a   Serra, Giuseppe ^a   Ratti, Deborah ^a   Gallotta, Giulia ^a   Vacchini, Daniela ^a   Tremolada, Ylenia ^a   Lazzarin, Adriano ^a   Clementi, Massimo ^a,b   Castagna, Antonella ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Diagnostica and Ricerca San Raffaele   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Drug resistance; Human immunodeficiency Virus, HIV; In vivo fitness; K103N mutation; Non nucleoside reverse transcriptase inhibitors; Reverse transcriptase; Treatment interruption

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; DNA SEQUENCE; DRUG EFFECT; GENETIC SELECTION; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PHYSIOLOGY; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SELECTION (GENETICS); SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 29244472063     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. BARBOUR, J.D., WRIN, T., GRANT, R.M., MARTIN, J.N., SEGAL, M.R., PETROPOULOS, C.J., DEEKS, S.G. (2002). Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. Journal of Virology, 76, 11104-11112.
2. th Conference on Retroviruses and Opportunistic Infections, February 8-11, San Francisco, CA. [Abstract 684].
3. COLLINS, J.A., THOMPSON, M.G., PAINTSIL, E., RICKETTS, M., GEDZIOR, J., ALEXANDER, L. (2004). Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. Journal of Virology, 78, 603-611.
4. DEEKS, S.G., WRIN, T., LIEGLER, T., HOH, R., HAYDEN, M., BARBOUR, J.D., HELLMANN, N.S., PETROPOULOS, C.J., MCCUNE, J.M., HELLERSTEIN, M.K., GRANT, R.M. (2001a). Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New England Journal of Medicine, 344, 472-480.
5. DEEKS, S.G. (2001b). International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. Journal of the Acquired Immune Deficiency Syndrome, 26 (Suppl 1): S25-S33.
6. DIALLO, K., GOTTE, M., WAINBERG, M.A. (2003). Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy, 47, 3377-3383.
7. HUANG, W., WRIN, T., GAMARNIK, A., BEAUCHAINE, J., WHITCOMB, J.M., PETROPOULOS, C.J. (2002). Reverse transcriptase mutations that confer non-nucleoside reverse transcriptase inhibitor-resistance may also impair replication capacity. Antiviral Therapy, 7, S60. [Abstract 72].
8. JOHNSON, V.A., BRUN-VEZINET, F., CLOTET, B., CONWAY, B., KURITZKES, D.R., PILLAY, D., SCHAPIRO, J., TELENTI, A., RICHMAN, D. (2005). Update of the Drug Resistance Mutations in HIV-1: 2005. Topics in HIV Medicine, 13, 51-57.
9. JOLY, V., DESCAMPS, D., PEYTAVIN, G., TOUATI, F., MENTRE, F., DUVAL, X., DELARUE, S., YENI, P., BRUN-VEZINET, F. (2004). Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrobial Agents and Chemotherapy, 48, 172-175.
10. th Conference on Retroviruses and Opportunistic Infections, February 24-28, Seattle, WA. [Abstract 95].
11. MARTINEZ-PICADO, J., SAVARA, A.V., SUTTON, L., D'AQUILA, R.T. (1999). Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. Journal of Virology, 73, 3744-3752.
12. MENZO, S., MONACHETTI, A., BALOTTA, C., CORVASCE, S., RUSCONI, S., PAOLUCCI, S., BALDANTI, F., BAGNARELLI, P., CLEMENTI, M. (2003). Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS, 17, 663-671.
13. nd International AIDS Society Conference on HIV Pathogenesis and Treatment, July 13-16, Paris, France. [Abstract 553].
14. NICASTRI, E., SARMATI, L., D'ETTORE, G., PALMISANO, L., PARISI, S.G., UCCELLA, I., RIANDA, A., CONCIA, E., VULLO, V., VELLA, S., ANDREONI, M. (2003). Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. Journal of Medical Virology, 69, 1-6.
15. PIKETTY, C., GÉRARD, L., CHAZALLON, C., CALVEZ, V., CLAVEL, F., TABURET, A.M., GIRARD, P.M., ABOULKER, J.P. and the ANRS 107 Puzzle 2 Study Group. (2004). Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures. AIDS, 18, 1469-1471.
16. SHAFER, R.W., SMEATON, L.M., ROBBINS, G.K., DE GRUTTOLA, V., SNYDER, S.W., D'AQUILA, R.T., JOHNSON, V.A., MORSE, G.D., NOKTA, M.A., MARTINEZ, A.I., GRIPSHOVER, B.M., KAUL, P., HAUBRICH, R., SWINGLE, M., MCCARTY, S.D., VELLA, S., HIRSCH, M.S., MERIGAN, T.C., AIDS Clinical Trials Group 384 Team. (2003). Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine, 349, 2304-2315.
17. WHITE, K.L., MARGOT, N.A., WRIN, T., PETROPOULOS, C.J., MILLER, M.D., NAEGER, L.K. (2002). Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrobial Agents and Chemotherapy, 46, 3437-3446.
18. WIRDEN, M., DELAGUERRE, C., MARCELIN, A.G., KTORZA, N., AIT MOHAND, H., DOMINGUEZ, S., SCHNEIDER, L., GHOSN, J., PAUCHARD, M., COSTAGLIOLA, D., KATLAMA, C., CALVEZ, V. (2004). Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrobial Agents and Chemotherapy, 48, 644-647.
19. ZACCARELLI, M., PERNO, C.F., FORBICI, F., CINGOLANI, A., LIUZZI, G., BERTOLI, A., TROTTA, M.P., BELLOCCHI, M.C., DI GIAMBENEDETTO, S., TOZZI, V., GORI, C., D'ARRIGO, R., DE LONGIS, P., NOTO, P., GIRARDI, E., DE LUCA, A., ANTINORI, A. (2003). Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antiviral Therapy, 8, 51-56.